ADMA Biologics, Inc. (ADMA)
Dopo ore:
| Chiusura precedente | 2,5100 |
| Aperto | 2,4700 |
| Denaro | 2,4500 x 4000 |
| Lettera | 2,5400 x 3200 |
| Min-Max giorno | 2,4700 - 2,6450 |
| Intervallo di 52 settimane | 1,0100 - 2,6450 |
| Volume | |
| Media Volume | 2.627.766 |
| Capitalizzazione | 500,71M |
| Beta (5 anni mensile) | 1,02 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,4900 |
| Prossima data utili | 08 nov 2022 - 14 nov 2022 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 4,67 |
- GlobeNewswire
ADMA Biologics Announces Second Quarter 2022 Financial Results and Provides Business Update
2Q2022 Total Revenues Were $33.9 Million, a 90% Y-o-Y Increase Grew 2Q2022 Gross Profit to $7.8 Million, Up 112% Over 1Q2022 Narrowed 2Q2022 Net Losses to $13.8 Million, a 45% Improvement Over 1Q2022 Full Year 2022 Total Revenues Expected to Exceed $130 Million Gross Margin Growth and Narrowing Net Losses Expected Throughout 2022 and Beyond Conference Call Scheduled for Today at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., Aug. 10, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA)
- GlobeNewswire
ADMA Biologics to Report Second Quarter 2022 Financial Results on August 10, 2022
Conference Call Scheduled for August 10, 2022, at 4:30 p.m. ETRAMSEY, N.J. and BOCA RATON, Fla., Aug. 03, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it will report financial results for the second quarter ended June 30, 2022, on Wednesday, August 10, 2022, after the U.S. financial markets clos
- GlobeNewswire
ADMA Biologics Announces Addition to the Russell 2000® Index
Ramsey, N.J. and Boca Raton, Fla., June 21, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that the Company will be added to the Russell 2000® Index, effective as of market open on June 27, 2022, according to a preliminary list of additions posted by FTSE Russell on June 17, 2022. The Russell 2000® Ind
